Major League Baseball (MLB) and the Major League Baseball Players Association (MLBPA) today released the annual public report from the Joint Drug Prevention and Treatment Program's Independent Program Administrator. The Joint Drug Prevention and Treatment Program calls for a public report to be issued each year. The accompanying report from the Independent Program Administrator, Jeffrey M. Anderson, M.D., covers the period from the beginning of the 2015-2016 off-season through the end of Major League Baseball's 2016 Postseason.
This report covers the time from the beginning of the 2015-2016 Major League Baseball off-season to the end of the 2016 Major League Baseball post-season (the "2016 Reporting Period"). As per agreement between the Office of the Commissioner of Baseball and the Major League Baseball Players Association, the following report is specific to Players who compose 40-man rosters for Major League Baseball Clubs.
1) The total number of drug tests that were conducted during the 2016 Reporting Period was 8,281 tests. Of this total number, the number of urine samples that were collected and analyzed for Performance Enhancing Substances, Stimulants and DHEA was 6,634. The number of blood samples that were collected and analyzed for the presence of human growth hormone (hGH) was 1,647.
2) Fifteen (15) adverse analytical findings were reported by the testing laboratory that resulted in discipline. Twelve (12) were for Performance Enhancing Substances and three (3) were for Stimulants. The substances reported were as follows:
Performance Enhancing Substances (12)
Dehydrochlormethyltestosterone (DHCMT): 5
Nandrolone, Drostanolone, and Stanozolol: 1
Testosterone and Chlortestosterone: 1 Stimulants (3) Adderall:
1 Methamphetamine/Amphetamine: 1 Methamphetamine: 1
3) One (1) non-analytical positive resulted in discipline.
4) 107 Therapeutic Use Exemptions were granted.
The diagnoses were as follows: Attention Deficit Disorder: 105 Hypercalciuria: 1 Hypertension: 1